Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;6(6):352-60.
doi: 10.1038/nrneph.2010.54. Epub 2010 Apr 27.

RAGE and the pathogenesis of chronic kidney disease

Vivette D'Agati  1 , Ann Marie Schmidt
Affiliations
Review

RAGE and the pathogenesis of chronic kidney disease

Vivette D'Agati et al. Nat Rev Nephrol. 2010 Jun.

Abstract

The multiligand receptor of the immunoglobulin superfamily, receptor for advanced glycation endproducts (RAGE), is a signal transduction receptor that binds advanced glycation endproducts, certain members of the S100/calgranulin family of proteins, high mobility group box 1 (HMGB1), advanced oxidation protein products, and amyloid (beta-sheet fibrils). Initial studies investigating the role of RAGE in renal dysfunction focused on diabetes. However, RAGE also has roles in the pathogenesis of renal disorders that are not associated with diabetes, such as obesity-related glomerulopathy, doxorubicin-induced nephropathy, hypertensive nephropathy, lupus nephritis, renal amyloidosis, and ischemic renal injuries. Experiments that have employed transgenic mouse models, pharmacological blockade of RAGE, or genetic deletion or modification of RAGE indicate that modulation of RAGE expression or function affects the functional and pathological properties of these nephropathies. Accumulating evidence links RAGE to the pathogenesis of nephropathies, indicating that antagonism of RAGE might be a strategy for the treatment of chronic kidney disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Pharmacol Sci. 2005 Mar;97(3):305-11 - PubMed
    1. Biochim Biophys Acta. 2007 Oct;1770(10):1468-74 - PubMed
    1. Diabetes Metab. 2005 Feb;31(1):35-9 - PubMed
    1. J Clin Invest. 2001 Dec;108(12):1853-63 - PubMed
    1. J Am Soc Nephrol. 2007 Feb;18(2):539-50 - PubMed

Publication types

MeSH terms

Substances